帕罗西汀联合MECT治疗体像障碍对照的研究.docVIP

帕罗西汀联合MECT治疗体像障碍对照的研究 　　[摘要] 目的：探讨帕罗西汀联合MECT治疗体像障碍的临床疗效。方法：将26例体像障碍患者随机分为研究组、对照组各13例，两组均用帕罗西汀治疗，研究组联合MECT治疗。疗程8周。于治疗前及治疗第2、4、8周末采用鲁龙光体像障碍（BDD）量表、汉密顿焦虑量表（HAMA）评定临床疗效；TESS评定副反应。结果：两组均自治疗第2周末BDD量表及HAMA分值均开始下降，研究组低于对照组（P＜0.05），第8周末两组间差异有统计学意义（P＜0.01）。结论：帕罗西汀合并MECT治疗与单一帕罗西汀治疗BDD均有显著疗效，前者治疗效果更好，起效更快。 　　[关键词] 体像障碍；多参数无抽搐电休克治疗；帕罗西汀；汉密顿焦虑量表 　　[中图分类号] R74 [文献标识码]A[文章编号]1674-4721（2011）04（b）-041-02 　　 　　A comparative study of paroxetine combined with MECT in the treatment of body dysmorphic disorder. 　　LI Zhenyu 　　Luoyang Rongkang Hospital of Henan Province, Luoyang 471013, China 　　[Abstract] Objective: To evaluate the efficacy of paroxetine combined with MECT in the treatment of body dysmorphic disorder. Methods: 26 patients were randomly divided into study group (13 patients) and control group (13 patients). Paroxetine were given to all the patients in the treatment for 8 weeks. During the treatment course, the patients in study group were added to MECT. The therapeutic effectiveness and side effects were appraised with the Hamilton Depression Scale (HAMA) and Treatment Emergent Symptom Scale (TESS), respectively. Results: After running for 2 weeks the score of BDD and HAMA in both groups began to decline, declining rate in the study group was larger than that of the control group (P0.05). After the experiment running for 8 weeks, there was extremely significant difference (P0.01) between these two groups. Conclusion: Paroxetine shows high efficiency in the treatment of BBD, especially when combining with MECT, the therapeutic effect is much more better and faster. 　　[Key words] Body dysmorphic disorder; MECT; Paroxetine; HAMA 　　 　　体象障碍（BDD）又称为躯体变形障碍，是指个体在客观上躯体外表并不存在缺陷，或者有极其轻微的缺陷，但其主观想象具有奇特的丑陋而产生的极为痛苦的心理疾病[1]。以往常采用心理治疗与药物治疗相结合的治疗方法。本组在帕罗西汀治疗的同时联合多参数无抽搐电休克治疗（MECT）躯体形式障碍取得了满意疗效，随机作了对照观察，报道如下： 　　1 资料与方法 　　1.1 一般资料 　　选取2006年9月～2010年6月在本院心身疾病科住院的体像障碍患者为研究对象。入组标准：年龄18～39岁，符合DSM-Ⅳ体像障碍诊断标准[2]，无MECT禁忌证，家属同意并签字。共入组26例。按入院顺序随机分为研究组和对照组各13例。研究组男4例，女9例；平均年龄（33.8±3.9）岁，平均病程（